Systemic Therapeutics Corp. is a Canadian biotechnology company in the pre-clinical stage, specializing in developing novel therapies targeting the master regulator of lipid metabolism, sterol regulatory-element binding proteins (SREBP). The company’s first-in-class small molecule SREBP inhibitors aim to offer new treatment options for metabolic conditions, including dyslipidemia through the reduction of circulating PCSK9, and Non-Alcoholic Fatty Liver Disease.